Cardiac concerns associated with strontium ranelate

Expert Opinion on Drug Safety

Volumn 13, Issue 9, 2014, Pages 1209-1213

  Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiac safety; Myocardial infarction; Osteoporosis; Strontium ranelate

Indexed keywords

PLACEBO; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CORONARY ARTERY OCCLUSION; DRUG SAFETY; DYSLIPIDEMIA; HEART DISEASE; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; CONTRAINDICATIONS; FRACTURES, BONE; OSTEOPOROSIS; PATHOPHYSIOLOGY; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIOPHENES;

EID: 84906274998     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.939169     Document Type: Review

References (19)

1. European Medicines Agency. Strontium ranelate. Summary. of product characteristics. Available from: www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000560/WC500045525.pdf [Last accessed 31 January 2014]
2. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
3. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
4. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013;98:592-601
5. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95
6. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2011;23:1115-22
7. European Medicines Agency. Good pharmacovigilance practices. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document-listing/ document-listing-000345.jsp&mid=WC0b01ac058058f32c [Last accessed 20 March 2014]
8. European Medicines Agency. Assessment report - periodic safety update report (EPAR - Protelos-H-C-560-PSU31). Available from: www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Assessment-Report-Variation/human/000560/ WC500147168.pdf [Last accessed 3 February 2014]
9. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised, placebo-controlled trial. Ann Rheum Dis 2013;72:179-86
10. Kanis JA, Johansson H, Odén A, et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis: the impact of severe osteoporosis and contraindications [abstract OC25]. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases - WCO-IOF-ESCEO Seville 2014; 2 - 5 April 2014; Seville, Spain
11. Audran M, Jakob FJ, Palacios S, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 2013;33:2231-9
12. Cooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 2014;25:737-45
13. Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 2014;25:757-62
14. Svanström H, Pasternak B, Hviid A. Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 2014;73(6):1037-43
15. Donneau AF, Reginster JY. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int 2014;25:397-8
16. European Medicines Agency. European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions. Available from: www.ema.europa.eu/docs/en-GB/document-library/Press-release/2014/02/WC500161971. pdf [Last accessed 24 February 2014]
17. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011;89:91-104
18. Rizzoli R, Reginster JY. Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 2011;4:593-604
19. Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8